SynthesisFrontiers in oncology2026
The prognostic value of the pan-immune-inflammation value in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Immune checkpoint inhibitors (ICIs) show substantial therapeutic potential in advanced or metastatic solid malignancies, yet optimization of clinical benefit remains an unmet need. This systematic review and meta-analysis evaluates the pretreatment pan-immune-inflammation value (PIV) as a prognostic biomarker in ICI-treated solid tumors. Methods: We conducted comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science covering all records available up to January 2026. Hazard ratios (HRs) with 95% confidence intervals (CIs) were retrieved, and pooled analyses were performed using STATA 18.0 to quantify correlations between PIV and survival results. Overall survival (OS) was considered the primary outcome, with disease-free, progression-free, and recurrence-free survival (DFS/PFS/RFS) as secondary endpoints. Results: Twenty-two studies comprising 28 cohorts and 3,272 participants were incorporated. Multivariate meta-analysis detected that an elevated PIV was related to shorter OS (HR = 2.31; 95% CI: 2.02-2.65; P < 0.00001) and inferior DFS/PFS/RFS (HR = 1.79; 95% CI: 1.42-2.26; P < 0.00001). Subgroup analyses denoted that follow-up duration, geographic region, PIV cutoff definitions, and cancer type may have modified the predictive performance of PIV for DFS/PFS/RFS. Conclusions: Among patients receiving ICIs, an elevated pretreatment PIV may serve as a potentially useful adverse prognostic biomarker for survival outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261290575.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.